NBIX
Neurocrine Biosciences, Inc.
Stock
$143.18+2.47 (+1.76%)Close Oct 2, 2026
- Operating cash flow, 2025
- $783M
- YoY, 2025
- +31.5%
- 5-year CAGR
- +27.9%
Operating cash flow
Operating cash flow by fiscal year
| Period | Operating cash flow | YoY |
|---|---|---|
| 2025 | $783M | +31.5% |
| 2024 | $595M | +52.7% |
| 2023 | $390M | +14.9% |
| 2022 | $339M | +32.3% |
| 2021 | $257M | +12.3% |
| 2020 | $229M | +55.4% |
| 2019 | $147M | +45.0% |
| 2018 | $101M | — |
| 2017 | −$94M | — |
| 2016 | −$106M | — |
| 2015 | −$38M | — |
| 2014 | −$47M | — |
| 2013 | −$30M | — |
| 2012 | −$35M | — |
| 2011 | −$698K | — |
| 2010 | $50M | — |
| 2009 | −$53M | — |